Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future-Reference-Cited by-同舟云学术

Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future

Published:2023-02 Issue:2 Volume:24 Page:266-278
ISSN:1389-2010
Container-title:Current Pharmaceutical Biotechnology
language:en
Short-container-title:CPB

Author:

Pestov Nikolay B.¹²³^ORCID,Kolyasnikova Nadezhda M.¹^ORCID,Sanchez-Pimentel Jeanne P.¹,Barlev Nikolay A.¹²⁴^ORCID,Ishmukhametov Aidar A.¹^ORCID

Affiliation:

1. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Poselok Instituta Poliomielita 8 bd 17, Poselenie Moskovskiy, Moscow, 108819, Russia

2. Moscow Institute of Physics and Technology, Phystech School of Biological and Medical Physics, Laboratory of Molecular Oncology, 9 Institutskiy per., Dolgoprudny, Moscow Region, 141701, Russia

3. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Group of Cross-Linking Enzymes, Miklukho-Maklaya 16/10, Moscow, 117997, Russia

4. Institute of Biomedical Chemistry, Pogodinskaya 10, Moscow, 119435, Russia

Abstract

Abstract: The idea of using the lytic power of viruses against malignant cells has been entertained for many decades. However, oncolytic viruses gained broad attention as an emerging anti-cancer therapy only recently with the successful implementation of several oncolytic viruses to treat advanced melanoma. Here we review the history of oncolytic viruses in the Russian Federation and recent biotechnological advances in connection with the perspectives of their practical use against aggressive tumors such as glioblastoma or pancreatic cancer. A particular emphasis is made on novel applications of safe non-lytic virus-derived vectors armed with prodrug-converting enzyme transgenes. Rational improvement of oncotropism by conjugation with biopolymers and nanoformulations is also discussed.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmaceutical Science,Biotechnology

Reference129 articles.

1. Alberts P.; Tilgase A.; Rasa A.; Bandere K.; Venskus D.; The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur J Pharmacol 2018,837,117-126

2. Liang M.; Oncorine, the World First Oncolytic virus medicine and its update in China. Curr Cancer Drug Targets 2018,18(2),171-176

3. Haitz K.; Khosravi H.; Lin J.Y.; Menge T.; Nambudiri V.E.; Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol 2020,83(1),189-196

4. Nettelbeck D.M.; Leber M.F.; Altomonte J.; Angelova A.; Beil J.; Berchtold S.; Delic M.; Eberle J.; Ehrhardt A.; Engeland C.E.; Fechner H.; Geletneky K.; Goepfert K.; Holm P.S.; Kochanek S.; Kreppel F.; Krutzke L.; Kühnel F.; Lang K.S.; Marchini A.; Moehler M.; Mühlebach M.D.; Naumann U.; Nawroth R.; Nüesch J.; Rommelaere J.; Lauer U.M.; Ungerechts G.; Virotherapy in Germany-recent activities in virus engineering, preclinical development, and clinical studies. Viruses 2021,13(8),1420

5. Kelly E.; Russell S.J.; History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 2007,15(4),651-659

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the Power of Pancreatic Enzymes: A Comprehensive Guide;J PANCREAS;2024

2. Investigation of oncolytic potential of vaccine strains of yellow fever and tick-borne encephalitis viruses against glioblastoma and pancreatic carcinoma cell lines;Problems of Virology;2023-12-26

3. At the Crossroads of the cGAS-cGAMP-STING Pathway and the DNA Damage Response: Implications for Cancer Progression and Treatment;Pharmaceuticals;2023-12-01

4. Flaviviruses in AntiTumor Therapy;Viruses;2023-09-22

5. Development and application of oncolytic viruses as the nemesis of tumor cells;Frontiers in Microbiology;2023-06-12